Sagimet Biosciences Inc. (SGMT)
USD 5.25
(-11.62%)
USD 5.25
(-11.62%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -23.76 Million | -24.49 Million | -21.71 Million | -10.41 Million | -10.55 Million |
| Net Income | -27.87 Million | -30.49 Million | -24.44 Million | -11.37 Million | -14.26 Million |
| Depreciation & Amortization | - | 130 Thousand | 134 Thousand | 124 Thousand | 1000.00 |
| Deferred income taxes | - | - | - | - | -93 Thousand |
| Stock-based compensation | 4.99 Million | 1.88 Million | 1.9 Million | 775 Thousand | 2.98 Million |
| Change in working capital | -978 Thousand | 4.21 Million | -55 Thousand | 75 Thousand | 645 Thousand |
| Other non-cash items | 98 Thousand | -85 Thousand | 883 Thousand | 104 Thousand | 168 Thousand |
| Investing Cash Flow | 12.58 Million | -32.01 Million | - | 20 Thousand | -27 Thousand |
| Investments in PPE | - | - | - | - | - |
| Acquisitions | - | - | - | 20 Thousand | - |
| Investment purchases | -19.62 Million | -41.44 Million | - | - | - |
| Sales/Maturities of investments | 32.2 Million | 9.43 Million | - | - | - |
| Other Investing Activities | 12.58 Million | -32 Million | - | 20 Thousand | -27 Thousand |
| Financing Cash Flow | 86.16 Million | -73 Thousand | 9.73 Million | 68.88 Million | 18.48 Million |
| Debt repayment | - | - | - | - | -3.36 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 89.67 Million | 12 Thousand | 10.99 Million | 68.88 Million | 21.84 Million |
| Other Financing Activities | -3.51 Million | -73 Thousand | 9.73 Million | 68.88 Million | 21.84 Million |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | 120 Thousand | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | -120 Thousand | 1.29 Million | -615 Thousand | 436 Thousand | -633 Thousand |
| Cash at beginning of period | 158 Thousand | 56.73 Million | 68.7 Million | 10.21 Million | 2.3 Million |
| Cash at end of period | 75.13 Million | 158 Thousand | 56.73 Million | 68.7 Million | 10.21 Million |
| Capital Expenditure | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 74.98 Million | -56.57 Million | -11.97 Million | 58.49 Million | 7.9 Million |
| Free Cash Flow | -23.76 Million | -24.49 Million | -21.71 Million | -10.41 Million | -10.55 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -8.11 Million | -6.62 Million | -27.87 Million | -8.15 Million | -6.35 Million | -6.78 Million |
| Depreciation & Amortization | - | - | - | - | 35 Thousand | 34 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 1.44 Million | 759 Thousand | 4.99 Million | 1.31 Million | 1.85 Million | 1.05 Million |
| Change in working capital | 1.47 Million | -181 Thousand | -978 Thousand | -280 Thousand | 588 Thousand | -21 Thousand |
| Other non-cash items | 1 Million | 36 Thousand | 98 Thousand | 37 Thousand | 31 Thousand | 29 Thousand |
| Investing Cash Flow | -75.15 Million | 3 Million | 12.58 Million | -19.62 Million | - | 12.8 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -82.95 Million | - | -19.62 Million | -19.62 Million | - | - |
| Sales/Maturities of investments | 7.79 Million | 3 Million | 32.2 Million | - | - | 12.8 Million |
| Other Investing Activities | -75.15 Million | 3 Million | 12.58 Million | -19.62 Million | - | 12.8 Million |
| Financing Cash Flow | -27 Thousand | 104.84 Million | 86.16 Million | 3.51 Million | 87.21 Million | -910 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 105.75 Million | 89.67 Million | 3.51 Million | 86.16 Million | - |
| Other Financing Activities | -27 Thousand | -1.01 Million | -3.51 Million | -3.51 Million | 87.21 Million | -910 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | -782 Thousand | 120 Thousand | 120 Thousand | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 1.47 Million | 601 Thousand | -120 Thousand | -600 Thousand | -802 Thousand | 376 Thousand |
| Cash at beginning of period | 176.77 Million | 75.13 Million | 158 Thousand | 101.84 Million | 18.5 Million | 12.33 Million |
| Cash at end of period | 95.95 Million | 176.77 Million | 75.13 Million | 75.13 Million | 101.84 Million | 18.5 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | -3.51 Million | - | - |
| Net cash flow / Change in cash | -80.81 Million | 101.63 Million | 74.98 Million | -26.7 Million | 83.33 Million | 6.17 Million |
| Free Cash Flow | -5.63 Million | -6.2 Million | -23.76 Million | -7.08 Million | -3.87 Million | -5.72 Million |
ALEGF
SXYAY
AQST
300548
CSLM
688690